KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
A phase 2 trial of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, run by Kartos Therapeutics, Inc., active and no longer recruiting.
Overview
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera is a phase 2 interventional study registered as NCT03669965 by Kartos Therapeutics, Inc., with 20 participants enrolled, started 2019-01-15 and due to reach its primary completion in 2022-04. Interventions recorded: KRT-232 and Ruxolitinib.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtended Access of Momelotinib in Adults With Myelofibrosis
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.